AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

SNY · NASDAQ · Drug Manufacturers - General

Sanofi (ADR) (SNY)

Develops immunology-focused medicines and vaccines across a broad international footprint.

$42.31

vs last close−0.20 (−0.46%)

In millions of USD, except per-share figures · converted from EUR at the latest rate

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	14,542	13,973	11,138	13,033	16,213	8,739	12,146	12,294	15,082	13,977	12,877	14,086
Cost of revenue	4,399	4,636	3,400	3,905	4,678	2,601	3,309	3,426	3,907	4,157	3,594	3,455
Gross profit	10,143	9,337	7,738	9,127	11,535	6,138	8,838	8,867	11,175	9,820	9,283	10,631
	6,466	8,945	6,323	7,301	7,372	5,482	6,280	7,179	7,026	11,009	6,685	7,901
Research & development	1,904	2,144	1,913	1,951	2,121	2,427	2,071	2,186	2,100	2,624	2,001	2,557
	2,954	3,357	2,418	3,041	3,070	1,422	2,738	3,012	2,624	2,749	2,856	3,016
Selling & marketing	0	0	0	0	0	0	194	0	0	0	191	194
General & administrative	0	0	0	0	0	0	2,545	0	0	0	2,665	2,823
Other expenses	1,608	3,445	1,993	2,309	2,180	1,633	1,472	1,981	2,302	5,637	1,828	2,327
Operating income	3,677	392	1,415	1,827	4,163	656	2,557	1,688	4,149	−1,189	2,598	2,730
	−126	−677	−164	−205	−62	−140	−38	−8	−132	−134	−292	−1,782
Interest income	164	321	168	296	152	212	98	177	131	27	69	88
Interest expense	364	337	283	348	303	346	244	231	260	−115	204	329
Other non-operating income	−164	563	−168	78	−152	251	−158	−42	−131	−3,309	101	1,443
Income before tax	3,551	−285	1,252	1,622	4,101	516	2,519	1,680	4,017	−1,323	2,306	948
Income tax expense	645	354	119	342	844	5	551	263	779	−399	481	516
Net income from continuing operations	2,907	−639	1,133	1,279	3,257	512	1,969	1,417	3,239	−924	1,825	432
Discontinued operations	0	0	180	0	0	0	199	3,100	−23	15	30	0
Other adjustments	0	0	0	0	0	73	0	0	0	0	0	0
Net income	2,892	−636	1,298	1,275	3,224	571	2,144	4,512	3,209	−917	1,848	393
EPS, basic	$1.15	−$0.25	$0.53	$0.52	$1.29	$0.40	$0.87	$1.83	$1.32	−$1.69	$0.77	$0.16
EPS, diluted	$1.15	−$0.25	$0.53	$0.52	$1.29	$0.40	$0.87	$1.83	$1.31	−$1.67	$0.77	$0.16
Weighted average shares, basic	2,506	2,507	2,498	2,502	2,506	2,507	2,468	2,468	2,436	2,441	2,408	2,393
Weighted average shares, diluted	2,506	2,507	2,498	2,502	2,506	2,507	2,468	2,468	2,468	2,441	2,408	2,393
EBITDA	4,485	487	2,138	2,320	4,864	645	3,172	2,163	4,808	4,378	3,110	1,919
Depreciation & amortization	644	658	554	571	549	239	457	433	528	2,258	613	632
EBIT	3,841	−172	1,584	1,749	4,315	405	2,715	1,730	4,280	2,120	2,498	1,287